Trial Profile
A Retrospective study of Bendamustine-Bortezomib-Desametasone (BVD) in patients with Relapsed and Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Pegfilgrastim
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology